D3 Bio Achieves FDA Clearance to Advance Innovative Cancer Trials with Two New IND Applications D3 Bio has received FDA clearance for two IND applications, paving the way for crucial cancer trials involving new therapeutics targeting KRAS mutations.

D3 Bio Achieves FDA Clearance to Advance Innovative Cancer Trials with Two New IND Applications #Shanghai #USA #KRAS_G12D #D3_Bio #elisrasib

D3 Bio Raises $108 Million to Propel Oncology Therapeutics Forward Globally D3 Bio has successfully raised $108 million in Series B financing, aimed at enhancing their global oncology drug development initiatives and advancing their promising clinical programs.

D3 Bio Raises $108 Million to Propel Oncology Therapeutics Forward Globally #Shanghai #USA #D3_Bio #oncology_therapeutics #elisrasib